Zelluna announced that ZIMA-101, its lead TCR-NK product, will be trialed at The Christie and The Royal Marsden NHS Foundation Trusts.
1 report, 1 independent
Updated Jun 29
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Zelluna announced that ZIMA-101, its lead TCR-NK product, will be trialed at The Christie and The Royal Marsden NHS Foundation Trusts.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
The Royal Marsden NHS Foundation Trust
English cancer hospital
Nothing else this week.